Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial*

This publication has 6 references indexed in Scilit:

• Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*
  Critical Care Medicine, 2005
• FDA Evaluation of Antimicrobials
  Chest, 2005
• Substantiating the concerns about recombinant human activated protein C use in sepsis*
  Critical Care Medicine, 2004
• Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
  Critical Care Medicine, 2003
• Risks and Benefits of Activated Protein C Treatment for Severe Sepsis
  New England Journal of Medicine, 2002
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001